These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38730654)

  • 1. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon.
    Bellman V
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Perilous Policy of Oregon's Psilocybin Services.
    Holoyda B
    J Am Acad Psychiatry Law; 2023 Jun; 51(2):160-166. PubMed ID: 37311597
    [No Abstract]   [Full Text] [Related]  

  • 3. Early Performance in Medicaid Accountable Care Organizations: A Comparison of Oregon and Colorado.
    McConnell KJ; Renfro S; Chan BK; Meath TH; Mendelson A; Cohen D; Waxmonsky J; McCarty D; Wallace N; Lindrooth RC
    JAMA Intern Med; 2017 Apr; 177(4):538-545. PubMed ID: 28192568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin in Palliative Care: An Update.
    Whinkin E; Opalka M; Watters C; Jaffe A; Aggarwal S
    Curr Geriatr Rep; 2023; 12(2):50-59. PubMed ID: 37305379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.
    Shah FI; Shehzadi S; Akram F; Haq IU; Javed B; Sabir S; Kazim Y; Ashfaq S
    Mol Biotechnol; 2023 Dec; ():. PubMed ID: 38117395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trip Through Employment Law: Protecting Therapeutic Psilocybin Users in the Workplace.
    Sheppard B
    J Law Health; 2021; 35(1):146-180. PubMed ID: 35026878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oregon's experience: evaluating the record.
    Lindsay RA
    Am J Bioeth; 2009 Mar; 9(3):19-27. PubMed ID: 19247883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress.
    Wang JR; Mendez Araque SJ; Micciche G; McMillan A; Coughlin E; Mattiola R; English D; Kaliebe K
    Front Psychiatry; 2024; 15():1301960. PubMed ID: 38699449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oregon's guidelines for physician-assisted suicide: a legal and ethical analysis.
    O'Brien CN; Madek GA; Ferrera GR
    Univ Pittsbg Law Rev; 2000; 61(2):329-65. PubMed ID: 12625322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
    Belouin SJ; Averill LA; Henningfield JE; Xenakis SN; Donato I; Grob CS; Berger A; Magar V; Danforth AL; Anderson BT
    Neuropharmacology; 2022 Nov; 219():109214. PubMed ID: 35973601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole Systems Within Whole Systems: The Oregon Health Plan's Expansion of Services for Back and Neck Pain.
    Eaves ER; Hsu CW; DeBar LL; Livingston CJ; Ocker LE; McDonald SJ; Dillon-Sumner L; Ritenbaugh C
    J Altern Complement Med; 2019 Mar; 25(S1):S61-S68. PubMed ID: 30870022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.
    Wolfgang AS; Hoge CW
    Curr Psychiatry Rep; 2023 Oct; 25(10):513-532. PubMed ID: 37682446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.
    Bhuiya NMA; Jacobs RJ; Wang K; Sun Y; Nava B; Sampiere L; Yerubandi A; Caballero J
    Cureus; 2023 Sep; 15(9):e45169. PubMed ID: 37842360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collaboration between Oregon's chronic disease programs and Medicaid to decrease smoking among Medicaid-insured Oregonians with asthma.
    Rebanal RD; Leman R
    Prev Chronic Dis; 2005 Nov; 2 Spec no(Spec No):A12. PubMed ID: 16263045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forest and farmland conservation effects of Oregon's (USA) land-use planning program.
    Kline JD
    Environ Manage; 2005 Apr; 35(4):368-80. PubMed ID: 15902442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Medical Students' Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice.
    Wang K; Sun Y; Nava B; Sampiere L; Jacobs RJ
    Cureus; 2023 Apr; 15(4):e37450. PubMed ID: 37181969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.
    Tai SJ; Nielson EM; Lennard-Jones M; Johanna Ajantaival RL; Winzer R; Richards WA; Reinholdt F; Richards BD; Gasser P; Malievskaia E
    Front Psychiatry; 2021; 12():586682. PubMed ID: 33643087
    [No Abstract]   [Full Text] [Related]  

  • 19. Building the foundation for health system transformation: Oregon's Patient-Centered Primary Care Home program.
    Rissi JJ; Gelmon S; Saulino E; Merrithew N; Baker R; Hatcher P
    J Public Health Manag Pract; 2015; 21(1):34-41. PubMed ID: 25414954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.